The Molecular Dynamics Effects of Rutin on CDKS 2, 4 and 6: In Silico Modelling and Molecular Dynamics
Objectives: This simulated study has mechanistically evaluated the molecular dynamics effects of rutin on CDKs 2, 4, and 6 in cell cycling.
Methods: Protein Data Bank (http://www.rcsb.org) was used to obtain the PDB file of CDK 2, 4, and 6. After simulation of CDKs in Gromacs software, AutoDock 4.2 was used to run 200 stages of molecular docking of CDKs in the presence of the rutin. CDK 2, 4, and 6 were simulated in the presence of rutin after docking.
Results: Rutin had the highest tendency to bind the CDK-2 and CDK-6 via binding 16 and 18 residues in the binding site with hydrogen and hydrophobic bonds (respectively). Also, they had the highest amount of binding energy released. Rutin decreased total energy in CDKs and reduced the radius of gyration in CDK-2 and CDK-6 after docking. The secondary coil structure increased in CDK-2 and decreased in CDK-4 and 6.
Conclusion: Conformational changes in CDK2 and 6 via rutin can inhibit the activity of these proteins and subsequently arrest the cell cycle in phases G1, S, and G2, which can lead the damaged cell to cell repair or Apoptosis.
1. Zhang M, Zhang L, Hei R, Li X, Cai H, Wu X, et al. CDK inhibitors in cancer therapy, an overview of recent development. Am J Cancer Res 2021;11:1913.
2. Liu HL, Jiang WB, Xie MX. Flavonoids: recent advances as anticancer drugs. Recent Recent Pat Anticancer Drug Discov 2010;5:152–64. [CrossRef]
3. Ponte LGS, Pavan ICB, Mancini MCS, da Silva LGS, Morelli AP, Severino MB, et al. The hallmarks of flavonoids in cancer. Molecules 2021;26:2029. [CrossRef]
4. Kim KH, Lee KW, Kim DY, Park HH, Kwon IB, Lee HJ. Optimal recovery of high-purity rutin crystals from the whole plant of Fagopyrum esculentum Moench (buckwheat) by extraction, fractionation, and recrystallization. Biores Technol 2005;96:1709e1712. [CrossRef]
5. Chua LS. A review on plant-based rutin extraction methods and its pharmacological activities. J Ethnopharmacol 2013;150:805e817. [CrossRef]
6. Gullón B, Lú-Chau TA, Moreira MT, Lema JM, Eibes G. Rutin: A review on extraction, identification and purification methods, biological activities and approaches to enhance its bioavailability. Trends Food Sci Technol 2017;67:220–35. [CrossRef]
7. DSLD. Dietary supplement Label Database; 2016. Available at: https://dsld.nlm.nih.gov/dsld/. Accessed Oct 25, 2016.
8. Hosseinzadeh H, Nassiri-Asl M. Review of the protective effects of rutin on the metabolic function as an important dietary flavonoid. J Endocrinol Invest 2014;37:783–8. [CrossRef]
9. Farha AK, Gan RY, Li HB, Wu DT, Atanasov AG, Gul K, et al. The anticancer potential of the dietary polyphenol rutin: Current status, challenges, and perspectives. Crit Rev Food Sci Nutr 2022;62:832–59. [CrossRef]
10. Marmé D. Tumor angiogenesis: a key target for cancer therapy. Oncol Res Treat 2018;41:164. [CrossRef]
11. Teleanu R, Chircov C, Grumezescu A, Teleanu D. Tumor angiogenesis and anti-angiogenic strategies for cancer treatment. J Clin Med 2020;9:84. [CrossRef]
12. Lin J-P, Yang J-S, Lin J-J, Lai K-Ch, Lu H-F, Ma Ch-Y, et al. Rutin inhibits human leukemia tumor growth in a murine xenograft model in vivo. Environ Toxicol 2012;27:480–4 [CrossRef]
13. Perk AA, Shatynska-Mytsyk I, Gerçek YC, Boztas K, Yazgan M, Fayyaz S, et al. Rutin mediated targeting of signaling machinery in cancer cells. Cancer Cell Int 2014;14:124. [CrossRef]
14. Chen H, Miao Q, Geng M, Liu J, Hu Y, Tian L, et al. Anti-tumor effect of rutin on human neuroblastoma cell lines through inducing G2/M cell cycle arrest and promoting apoptosis. Sci World J 2013;2013:269165. [CrossRef]
15. Project E, Nachliel E, Gutman M. Force field dependant structural divergence revealed during long time simulations of Calbindin d9k. J Comput Chem 2010;31:1864–72. [CrossRef]
16. Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RK, et al. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J Comput Chem 1998;19:1639–62. [CrossRef]
17. Rather MA, Dutta S, Guttula PK, Dhandare BC, Yusufzai SI, Zafar MI. Structural analysis, molecular docking and molecular dynamics simulations of G-protein-coupled receptor (kisspeptin) in fish. J Biomol Struct Dyn 2020;38:2422–39. [CrossRef]
18. Tripathi SK, Muttineni R, Singh SK. Extra precision docking, free energy calculation and molecular dynamics simulation studies of CDK2 inhibitors. J Theorl Biol 2013;334:87–100.
19. Incandela L, Cesarone MR, DeSanctis MT, Belcaro G, Dugall M, Acerbi G. Treatment of diabetic microangiopathy and edema with HR (Paroven, Venoruton; 0-(beta-hydroxyethyl)-rutosides): a prospective, placebo-controlled, randomized study. J Cardiovasc Pharmacol Ther 2002;7:S11–5. [CrossRef]
20. Brüschweiler R. Efficient RMSD measures for the comparison of two molecular ensembles. Proteins 2003;50:26–34. [CrossRef]
21. Lobanov MY, Bogatyreva N, Galzitskaya O. Radius of gyration as an indicator of protein structure compactness. Mol Biol 2008;42:623–8. [CrossRef]
22. Vermeulen K, Van Bockstaele DR, Berneman ZN. The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolifer 2003;36:131–49. [CrossRef]
23. Arellano M, Moreno S. Regulation of CDK/cyclin complexes during the cell cycle. Int J Biochem Cell Biol 1997;29:559–73.
24. Bortolozzi R, Mattiuzzo E, Trentin L, Accordi B, Basso G, Viola G. Ribociclib, a Cdk4/Cdk6 kinase inhibitor, enhances glucocorticoid sensitivity in B-acute lymphoblastic leukemia (B-All). Biochem Pharmacol 2018;153:230–41. [CrossRef]
25. Malumbres M, Barbacid M. Mammalian cyclin-dependent kinases. Trends in Biochem Sci 2005;30:630–41. [CrossRef]
26. Yu M. Compounds, composition, methods, targets for cancer therapy. 2014; United States patent US 8, 680,129.
27. Ichim T, Koos D. Regen BioPharma Inc, assignee. Stimulation of immunity to tumor specific and endothelial specific proteins by in vivo dc attraction and maturation. 2016; United States patent application US 14/854,136.
28. Lal B, Joshi KS, Kulkarni SA, Mascarenhas M, Kamble SG, Rathos MJ, Joshi RD. Nicholas Piramal India Limited, assignee. Flavone derivatives as inhibitors of cyclin-dependent kinases. 2015; EP037539112004.
29. Perrier E, Mariotte AM, Boumendjel A, Bresson-Rival D. Flavonoide esters and their use notably in cosmetics. 2001; US 6,235,294 B1.
30. Li S, Liang X, Li D. Preparation method of trihydroxyethyl rutoside. Jinan Xinlite Technology Co., Ltd. 2016; US 2016/0096860 A1.